KEROS THERAPEUTICS INC
KROSNASDAQTrading Snapshot
- Day Range
- $11.21 – $11.88
- 52-Week Range
- $9.69 – $22.55
- Volume (shares)
- 205,017
- Avg Volume (shares)
- —
- Shares Outstanding
- 19.8M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- $244M
- Last Q Revenue
- —
- P/E Ratio
- -3.1
- P/S Ratio
- 15.0x
- EPS (TTM)
- $-4.20
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −32.6%
KEROS THERAPEUTICS INC
KROS
StockOtter · stockotter.spaceAbout KEROS THERAPEUTICS INC
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Keros Therapeutics Eyes 2027 DMD Data as Rinvatercept Takes Center Stage
Keros Therapeutics NASDAQ: KROS is repositioning its pipeline around rinvatercept, a skeletal-muscle regeneration candidate being developed for neuromuscular diseases, while its partnered program eleriscept advances thro
Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
Keros Therapeutics (NASDAQ: KROS - Get Free Report) and Upstream Bio (NASDAQ: UPB - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a w
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a w
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeu